Financial statements are reported in AUD. Prices converted from USD at today's exchange rate. Tranches and alerts stay in USD.
ATHE — Alterity Therapeutics Limited
A$ 2.89
A$ -0.20 (-6.44%)
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease.
Market Cap
A$ 55.24M
Forward P/E
-2.3x
52-Week Range
N/A
ATHE Price History
Revenue vs. Net Income
A$ 3.8M
Revenue · FY2026
Annual. Net margin is shown under each year.
Free Cash Flow
-A$ 22.5M
FCF · FY2026
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-58.5%
ROCE · FY2026
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
14.0x
Assets ÷ liabilities · FY2026
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
0.2%
CapEx · FY2024
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+64.5%
Dilution · FY2026
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
